Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2013
03/21/2013WO2013039167A1 Pharmaceutical composition for inhalation
03/21/2013WO2013039140A1 Fused heterocyclic derivative
03/21/2013WO2013039111A1 Nano-particles for internal radiation therapy of involved area, and therapy system
03/21/2013WO2013039057A1 Pyrrolidine-3-ylacetic acid derivative
03/21/2013WO2013038907A1 Method for inhibiting cell growth, nucleic acid molecule having rna interference effect on nek10 variant gene, and anticancer agent
03/21/2013WO2013038776A1 Therapeutic agent for inflammatory bowel disease
03/21/2013WO2013038740A1 Method for screening for substance or factor capable of promoting muscle hypertrophy
03/21/2013WO2013038666A1 Light-induced seizure model in rat brains
03/21/2013WO2013038430A1 SYNTHESIS OF 10-α/β-D-ARABINOFURANOSYL-UNDECENES AS POTENTIAL ANTI-MYCOBACTERIAL AGENTS
03/21/2013WO2013038429A2 Novel sglt inhibitors
03/21/2013WO2013038407A1 Amorphous form of dolutegravir
03/21/2013WO2013038390A1 N-substituted heterocyclyl carboxamides
03/21/2013WO2013038386A1 Heterocyclic compounds for the treatment of cystic fibrosis
03/21/2013WO2013038381A1 Pyridine/pyrazine amide derivatives
03/21/2013WO2013038378A1 Pyridine amide derivatives
03/21/2013WO2013038373A1 Pyridine amide derivatives
03/21/2013WO2013038362A1 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase
03/21/2013WO2013038351A1 Solid forms of a transthyretin dissociation inhibitor
03/21/2013WO2013038330A1 Nitrogen containing compounds and their use
03/21/2013WO2013038323A1 Taste masked pharmaceutical compositions of cefuroxime axetil
03/21/2013WO2013038308A1 SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS AS mPGES-1 INHIBITORS
03/21/2013WO2013038268A1 Tamper resistant immediate release formulations
03/21/2013WO2013038267A1 Tamper resistant pharmaceutical formulations
03/21/2013WO2013038259A1 Benzothiazinone derivatives as anti -tuberculosis agents
03/21/2013WO2013038200A2 Neurodevelopmental disorders
03/21/2013WO2013038197A1 Use of alginate oligomers to enhance the effects of antifungal agents
03/21/2013WO2013038195A2 Pharmaceutical nanoparticle compositions
03/21/2013WO2013038189A1 New enzyme inhibitor compounds
03/21/2013WO2013038157A1 Phytocannabinoids for use in the treatment of cancer
03/21/2013WO2013038136A1 BI-AROMATIC AND TRI-AROMATIC COMPOUNDS AS NADPH OXIDASE 2 (Nox2) INHIBITORS
03/21/2013WO2013038046A1 Use of trpa1 receptor antagonists for treating diseases associated with bacterial infections
03/21/2013WO2013037995A1 Sorbent comprising on its surface an aliphatic unit having an anionic or deprotonizable group for the purification of organic molecules
03/21/2013WO2013037985A1 Pharmaceutical combinations including anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders
03/21/2013WO2013037984A1 Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders
03/21/2013WO2013037964A1 Anticancer active ingredient derived from guiera senegalensis
03/21/2013WO2013037960A1 Ep1 receptor ligands
03/21/2013WO2013037943A1 Compositions and methods for treating cancer using pi3k beta inhibitor and mapk pathway inhibitor, including mek and raf inhibitors
03/21/2013WO2013037942A1 Synthesis of triazolopyrimidine compounds
03/21/2013WO2013037914A1 Substituted 4,5,6,7-tetrahydro-1h-pyrazolo[4,3-c]pyridines, their use as medicament, and pharmaceutical preparations comprising them
03/21/2013WO2013037905A1 Use of 3-(r)-[3-(2-methoxyphenylthio)-2-(s)-methylpropyl]amino-3,4-dihydro- 2h-1,5-benzoxathiepine for preventing and/or treating cardiotoxic effects caused by chemotherapy and/or radiation
03/21/2013WO2013037896A1 Disubstituted 5-fluoro-pyrimidines
03/21/2013WO2013037894A1 Disubstituted 5-fluoro pyrimidine derivatives containing a sulfoximine group
03/21/2013WO2013037883A1 New use of melatonine
03/21/2013WO2013037862A1 Specific phosphatidylcholines as modulators of platelet activation factor activity
03/21/2013WO2013037843A1 Formulation for the treatment of benign prostate hyperplasia
03/21/2013WO2013037838A1 Polymorphic form of pitavastatin calcium
03/21/2013WO2013037812A1 Sulfonic acid salts of heterocyclylamide-substituted imidazoles
03/21/2013WO2013037809A1 Tetrahydrotriazolopyrimidine derivatives as human neutrophil elastase inhibitors
03/21/2013WO2013037800A1 Use of 3-(r)-[3-(2-methoxyphenylthio)-2-(s)-methylpropyl]amino-3,4-dihydro- 2h-1,5-benzoxathiepine for treating cancer and in particular for preventing and/or treating cancer metastases
03/21/2013WO2013037794A1 Use of omega fatty acids for treating disease
03/21/2013WO2013037779A1 New dihydroquinoline-2-one derivatives
03/21/2013WO2013037768A1 Piperidine pyrazoles as fungicides
03/21/2013WO2013037753A1 Plant growth regulating compounds
03/21/2013WO2013037736A1 Indanyl-substituted 4,5,6,7-tetrahydro-1h-pyrazolo[4,3-c]pyridines, their use as medicament, and pharmaceutical preparations comprising them
03/21/2013WO2013037731A1 Novel polymorphic form of raltegravir potassium
03/21/2013WO2013037724A1 Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals
03/21/2013WO2013037721A1 5-cycloalkyl- or 5-heterocyclyl-nicotinamides
03/21/2013WO2013037713A1 Combinations comprising a s1p receptor modulator
03/21/2013WO2013037704A1 N-(5-cycloalkyl- or 5-heterocyclyl-)-pyridin-3-yl carboxamides
03/21/2013WO2013037703A1 3 -pyridine carboxylic acid hydrazides as hdl-cholesterol raising agents
03/21/2013WO2013037650A1 Compositions for oral administration to animals, production methods thereof and uses of same
03/21/2013WO2013037566A1 Aqueous compositions comprising arbekacin
03/21/2013WO2013037499A1 Inhibitors of nox4 expression and/or nox4 function and their use in the prevention and treatment of nerve injury and/or neuropathic pain
03/21/2013WO2013037482A1 Farnesoid x receptor agonists for cancer treatment and prevention
03/21/2013WO2013037479A1 Ophthtalmic compositions comprising prostaglandin f2 alpha derivatives and hyaluronic acid
03/21/2013WO2013037457A1 Topical pharmaceutical compositions
03/21/2013WO2013037415A1 Substituted 4,5,6,7-tetrahydro-1h-pyrazolo[4,3-c]pyridines, their use as medicament, and pharmaceutical preparations comprising them
03/21/2013WO2013037411A1 New enzyme inhibitor compounds
03/21/2013WO2013037390A1 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
03/21/2013WO2013037389A1 Indanyl-substituted 4,5,6,7-tetrahydro-1h-pyrazolo[4,3-c]pyridines, their use as medicament, and pharmaceutical preparations comprising them
03/21/2013WO2013037388A1 Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals
03/21/2013WO2013037333A1 6, 8- disubstituted purine compositions and their pharmaceutical and cosmetic use
03/21/2013WO2013037293A1 N-indol-1-amide compounds and application as anticancer medicament
03/21/2013WO2013037292A1 Substituted aromatic urea compound and use thereof as anti-cancer drug
03/21/2013WO2013037207A1 N-(3-pyridine formoxyl)- 3,5-dimethyl-1- amantadine or its pharmaceutical salt for treating vascular dementia
03/21/2013WO2013037129A1 Antitumour pharmaceutical composition with two active components and use thereof
03/21/2013WO2013037127A1 Antitumour pharmaceutical composition and use thereof
03/21/2013WO2013037065A1 Microrna inhibitors
03/21/2013WO2013037043A1 Combination therapy using ribavirin as eif4e inhibitor
03/21/2013WO2013036998A1 Treatment of bone diseases
03/21/2013WO2013036994A1 Compounds for the treatment of hcv
03/21/2013WO2013024493A8 C-9 oxygen functionalized labdane derivates
03/21/2013WO2013016668A3 Methylphenidate-prodrugs, processes of making and using the same
03/21/2013WO2013014654A3 Formulas comprising highly soluble elements and vitamin for the prevention and amelioration of osteoporosis
03/21/2013WO2013012954A3 Resorption enhancers as additives to improve the oral formulation of non-anticoagulant sulfated polysaccharides
03/21/2013WO2013009826A9 Conjugating amines
03/21/2013WO2013007763A9 MODULATORS OF THE NLRP3 INFLAMMASOME IL-1ß PATHWAY FOR THE PREVENTION AND TREATMENT OF ACNE
03/21/2013WO2013005042A3 Anti-viral therapy
03/21/2013WO2012168885A9 Bisacodyl and its analogues as drugs for use in the treatment of cancer
03/21/2013WO2012166859A3 Modulation of sphingosine 1-phosphate metabolizing enzymes for the treatment of negative-strand rna virus infections
03/21/2013WO2012164103A9 Blockers of the nogo-a s1pr pathway for the treatment of diseases characterized by neuronal damage and lack of subsequent repair
03/21/2013WO2012164055A3 New compounds, synthesis and use thereof in the treatment of pain
03/21/2013WO2012162578A3 Anti-viral compounds
03/21/2013WO2012162555A3 Heparin nanoclusters
03/21/2013WO2012162108A9 Boron-containing compositions and methods therefor
03/21/2013WO2012161520A3 Injectable liquid composition containing docetaxel
03/21/2013WO2012157984A3 Novel heteroaromatic compounds and use thereof
03/21/2013WO2012157978A3 Daphne genkwa extracts, and pharmaceutical composition containing fractions of the extracts or compounds separated from the extracts as active ingredients for preventing or treating atopic dermatitis
03/21/2013WO2012157949A3 Compound useful for preventing or treating irritable bowel syndrome and composition including same
03/21/2013WO2012157921A3 Composition for transdermal administration, containing rivastigmine or salt thereof
1 ... 788 789 790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 ... 7860